Previous Close | 16.62 |
Open | 16.60 |
Bid | 0.00 x 4000 |
Ask | 0.00 x 900 |
Day's Range | 15.21 - 16.83 |
52 Week Range | 12.24 - 28.06 |
Volume | |
Avg. Volume | 2,687,845 |
Market Cap | 2.618B |
Beta (5Y Monthly) | 0.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.33 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.13 |
Subscribe to Yahoo Finance Plus to view Fair Value for ACAD
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller. The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients. Initial data announced in April showed that the primary endpoint of pain intensity was not met. Rival Vertex boasted a mid-phase win for a similar candidate. Acadia has also discontinued ACP-319, which w
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?